tallózása szerző szerint "Lassaletta A"

A találatok rendezése: Rendezés: Találatok:

  • Stark D; Bielack S; Brugieres L; Dirksen U; Duarte X; Dunn S; Erdélyi, Dániel; Grew T; Hjorth L; Jazbec J; Kabickova E; Konsoulova A; Kowalczyk JR; Lassaletta A; Laurence V; Lewis I; Monrabal A; Morgan S; Mountzios G; Olsen PR; Renard M; Saeter G; van der Graaf WT; Ferrari A (2016)
    Over 14 000 patients aged 15-24 are estimated to be diagnosed with cancer in the European Union (EU) each year. Teenagers and young adults (TYA) often fall down gaps between children's and adults cancer services. The ...
  • Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Stucklin AG; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown, T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang SY; Snuderl M; Rao AN; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Conter CF; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser, Péter; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen SY; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U (2017)
    Purpose BRAF V600E is a potentially highly targetable mutation detected in a subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group of tumors remains unknown. Patients and ...